Table 3.
Associations between IgE sensitization, serum specific IgE scores and risk of incident cancer overall and by sex with chronological age as timescale.
| HR (95% CI) |
||||||||
|---|---|---|---|---|---|---|---|---|
| IgE sensitization |
Specific IgE scores§ |
|||||||
| n cancer/n total | No | Yes | 0 | 1–2 | 3–4 | 5–6 | Ptrend | |
| Both men and women | ||||||||
| n | 4714 | 4013 | 4714 | 6402 | 8331 | 8727 | ||
| Multivariable model | 689/8727 | 1.0 (Ref) | 0.88 (0.75–1.03) | 1.0 (Ref) | 1.00 (0.82–1.21) | 0.74 (0.59–0.93) | 0.91 (0.55–1.51) | 0.03 |
| Additional adjustment for total IgE | 689/8727 | 1.0 (Ref) | 0.83 (0.70–0.99) | 1.0 (Ref) | 0.95 (0.78–1.16) | 0.69 (0.54–0.88) | 0.79 (0.47–1.32) | 0.007 |
| Stratification by total IgE (kU/L) | ||||||||
| 191/2050 | 1.0 (Ref) | 0.79 (0.48–1.32) | 1.0 (Ref) | 0.86 (0.51–1.47) | 0.48 (0.12–1.99) | N/A | 0.29 | |
| 25–100 | 238/3292 | 1.0 (Ref) | 0.85 (0.64–1.13) | 1.0 (Ref) | 0.91 (0.65–1.28) | 0.77 (0.51–1.16) | N/A | 0.18 |
| ≥100 | 260/3385 | 1.0 (Ref) | 0.82 (0.63–1.06) | 1.0 (Ref) | 1.00 (0.74–1.34) | 0.66 (0.48–0.91) | 0.81 (0.47–1.39) | 0.02 |
| Men | ||||||||
| n | 1661 | 1945 | 1661 | 732 | 1003 | 210 | ||
| Multivariable model | 277/3606 | 1.0 (Ref) | 0.97 (0.76–1.23) | 1.0 (Ref) | 1.01 (0.75–1.36) | 0.89 (0.65–122) | 1.27 (0.64–2.52) | 0.80 |
| Additional adjustment for total IgE | 277/3606 | 1.0 (Ref) | 0.89 (0.69–1.17) | 1.0 (Ref) | 0.95 (0.69–1.29) | 0.83 (0.59–1.16) | 1.10 (0.54–2.23) | 0.42 |
| Stratification by total IgE (kU/L) | ||||||||
| <25 | 53/649 | 1.0 (Ref) | 0.71 (0.29–1.76) | 1.0 (Ref) | 0.59 (0.20–1.78) | 1.11 (0.27–4.67) | N/A | 0.64 |
| 25–100 | 97/1377 | 1.0 (Ref) | 0.83 (0.54–1.28) | 1.0 (Ref) | 0.99 (0.59–1.66) | 0.68 (0.38–1.23) | N/A | 0.24 |
| ≥100 | 127/1580 | 1.0 (Ref) | 0.97 (0.67–1.41) | 1.0 (Ref) | 1.00 (0.64–1.57) | 0.89 (0.57–1.40) | 1.23 (0.58–2.61) | 0.94 |
| Women | ||||||||
| n | 3053 | 2068 | 3053 | 956 | 926 | 186 | ||
| Multivariable model | 412/5121 | 1.0 (Ref) | 0.83 (0.67–1.03) | 1.0 (Ref) | 0.98 (0.76–1.27) | 0.64 (0.45–0.90) | 0.72 (0.34–1.53) | 0.01 |
| Additional adjustment for total IgE | 412/5121 | 1.0 (Ref) | 0.81 (0.64–1.02) | 1.0 (Ref) | 0.96 (0.74–1.24) | 0.61 (0.42–0.87) | 0.64 (0.30–1.39) | 0.01 |
| Stratification by total IgE (kU/L) | ||||||||
| <25 | 138/1401 | 1.0 (Ref) | 0.82 (0.44–1.53) | 1.0 (Ref) | 0.98 (0.53–1.83) | N/A | N/A | 0.30 |
| 25–100 | 141/1915 | 1.0 (Ref) | 0.87 (0.59–1.26) | 1.0 (Ref) | 0.85 (0.54–1.34) | 0.91 (0.52–1.58) | N/A | 0.51 |
| ≥100 | 133/1805 | 1.0 (Ref) | 0.73 (0.52–1.04) | 1.0 (Ref) | 0.98 (0.66–1.46) | 0.51 (0.31–0.83) | 0.63 (0.29–1.39) | 0.01 |
§
Highest specific IgE scores recorded at baseline.
N/A = not applicable; n = number of participants.
All models were adjusted for sex (except for sex-specific analysis), socioeconomic status, period of measurement and history of chronic pulmonary disease.